File a Clinical Trial Application for ALN-APP
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Feb 2021
- Due
- 30 Jun 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“advancement of ALN-APP, in development for the treatment of cerebral amyloid angiopathy (CAA) and autosomal dominant Alzheimer’s Disease (ADAD), with an expected CTA filing in mid-2021.”
What we found
Evidence strength A What the grades mean
The company missed the mid-2021 deadline, announcing in an August 2021 filing that the CTA filing for ALN-APP was delayed to late 2021.
-
A Alnylam Pharmaceuticals, Inc. 8-K filed 2021-08-03
“with a CTA filing now planned for late 2021” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- Clinical Trial Application for ALN-APP
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Alnylam Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ALNY-023583 · Corrections policy